الجمعة 12 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome | Takeda | Rejected | Alogliptin | 3 | SYR-322_402 | N\A |
| A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes. | GW | Rejected | Cannabidiol & Tetrahydrocannabivarin | 2a | GWZMD1190 | N\A |
| "A RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED, PILOT, DOSE-RANGING STUDY TO ASSESS THE EFFECT OF GWP42003 ON LIVER FAT LEVELS IN SUBJECT WITH FATTY LIVER DISEASE" | GW | Rejected | Cannabidiol | 2a | GWZMD1188 | N/A |
| A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age | GSK | Rejected | Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612 | 3b | 114858 | N\A |
| A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. | Novartis | Rejected | Everolimus + Exemestane\Everolimus\Capecitabine | 2 | CRAD001Y2201 | N\A |
| "“MERS-CoV Infection Treated with a Combination ofLopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-BlindRandomized Trial (MIRACLE Trial)”" | KAIMRC | Ongoing | Kaletra | 3 | RC15/142/R | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital NG (Al Ahsa), Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Genaral Hospital, Medina, prince mohammad bin abdulaziz hospital (Riyadh), ohud hospital (Medina), Buraidah Central Hospital HOME - Buraydah, Aseer Central Hospital |
| "Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial" | London School of Hygiene & Tropical Medicine (LSHTM) | Ongoing | (Cyklokapron) Tranexamic Acid | 3 | ISRCTN15088122 | King Saud Medical City (Riyadh) |
| EXPERT, EXPosurE Registry RiociguaT in patients with pulmonary hypertension | Bayer | Ongoing | Riociguat | 4 | 16657 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients in EMEA countries. | Bayer | Ongoing | Riociguat | 4 | 18303 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD) | Bayer | Terminated | Finerenone | 3 | BAY 94-8862 17530 | King Abdulaziz University Hospital (Jeddah) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.